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Abstract: An increased adipocyte size relative to the size of fat depots, also denoted hypertrophic 
adipose morphology, is a strong risk factor for the future development of insulin resistance and type 
2 diabetes. The regulation of adipose morphology is poorly understood. We set out to identify 
genetic loci associated with adipose morphology and functionally evaluate candidate genes for 
impact on adipocyte development. We performed a genome-wide association study (GWAS) in the 
unique GENetics of Adipocyte Lipolysis (GENiAL) cohort comprising 948 participants who have 
undergone abdominal subcutaneous adipose biopsy with a determination of average adipose 
volume and morphology. The GWAS identified 31 genetic loci displaying suggestive association 
with adipose morphology. Functional evaluation of candidate genes by small interfering RNAs 
(siRNA)-mediated knockdown in adipose-derived precursor cells identified six genes controlling 
adipocyte renewal and differentiation, and thus of potential importance for adipose hypertrophy. 
In conclusion, genetic and functional studies implicate a regulatory role for ATL2, ARHGEF10, 
CYP1B1, TMEM200A, C17orf51, and L3MBTL3 in adipose morphology by their impact on 
adipogenesis. 
Keywords: adipose morphology; adipogenesis; genome-wide association study (GWAS); genetic 
loci; GENetics of Adipocyte Lipolysis (GENiAL) cohort 
 
1. Introduction 
Excess adipose tissue plays a central role in the risk of developing insulin resistance (IR) and, 
thereby, the development of type 2 diabetes (T2D). However, it is not only the size but also the 
morphology of subcutaneous adipose tissue (SAT), which influences adipose function [1,2]. The 
number of fat cells differs substantially between individuals, even among those with the same total 
body fat, which can be classified as either hypertrophic, i.e., fewer but larger fat cells, or hyperplastic, 
i.e., more but smaller fat cells, adipose morphology [3,4]. Hypertrophic SAT is the pernicious 
morphology and has been associated with IR and T2D [5,6]. Hypertrophic SAT has been linked to 
local IR and increased release of pro-inflammatory mediators and free fatty acids within SAT [5,6], 
which through systemic effects, contribute to IR. 
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The factors governing SAT hyperplastic versus hypertrophic expansion is poorly understood. 
Human SAT contains a pool of progenitor cells that are continuously recruited to the adipose lineage 
to mature adipocytes [3]. Hypertrophic adipose morphology has been associated with reduced 
numbers of new adipocytes [4,6] and altered extracellular matrix function [7]. Adipocytes are turned 
over slowly [4], and adipose morphology is, thus, a relatively stable phenotype over time. 
Importantly, the observation that bariatric surgery induces a hyperplastic adipose morphology, 
which is associated with beneficial systemic metabolic parameters in comparison to body mass index 
(BMI)-matched controls, gives support to the notion that treatments improving adipose morphology 
have potential as therapeutic targets for IR and T2D [8]. 
First degree relatives of patients with T2D have been characterized as having hypertrophic 
adipose tissue consistent with a genetic impact on adipose morphology and link to IR/T2D [9]. 
Recently, large genome-wide association studies (GWAS) have identified hundreds of genetic risk 
loci for IR and T2D, and have reported that subjects carrying certain risk alleles exhibit reduced SAT 
indicating that inability of proper SAT expansion and body fat distribution are important 
contributing factors for the risk of developing metabolic disease [10]. There is evidence that body fat 
distribution and adipose morphology are related [7]. However, to the best of our knowledge, up to 
now, no GWAS has directly addressed the genetic regulation of adipose morphology, and its role in 
development of IR/T2D. 
In the present study, we conducted a GWAS for adipose morphology to identify genetic loci 
associated with, and highlight potential variants influencing adipose morphology. Adipose 
morphology was assessed using average adipocyte size in the abdominal SAT region adjusted for the 
size of the fat depot; a positive value is indicative of larger than expected adipocytes in relation to 
body fat mass (hypertrophy), and a negative value indicates hyperplasia [11]. Candidate genes in 
adipose morphology-associated loci were taken forward for functional evaluation, with in vitro 
experiments in adipocytes being used to determine the impact on phenotypes central to the 
development of adipose hypertrophy, i.e., precursors cell proliferation and adipocyte differentiation.  
2. Materials and Methods 
2.1. Participants 
The GENiAL cohort has been described previously [12]. In the present study, we included all 
948 participants for which SAT adipocyte size had been measured to determine adipose morphology 
(Supplementary Figure 1). Descriptives of the study subjects are presented in Table 1. Fifty-seven 
percent were obese (defined as BMI >30kg/m2). Total body fat mass was indirectly calculated using a 
formula based on age, sex, and BMI [13]. A venous blood sample was obtained for the extraction of 
DNA and clinical chemistry analyses by the hospital’s accredited routine clinical chemistry 
laboratory. All participants lived in Stockholm county, Sweden. One hundred and ninety-four 
participants had type 2 diabetes, hypertension, or dyslipidemia alone or in different combinations. 
None were treated with insulin, glitazones, or glucagon-like-peptide analogs. Data on clinical and 
adipose variables have been published previously [14,15]. The study was approved by the local 
committee on ethics at the Huddinge University Hospital (D. no. 167/02, 2002-06-03) and explained 
in detail to each participant. Informed consent was obtained from all participants; this was in written 
form since 1996. 
SAT gene expression was studied in 114 women, which is a subset of the above cohort. This 
cohort has been described previously [16] and contained the same type of adipose data as presented 
herein, with the exception that adipose morphology was calculated by relating average adipose 
volume to total body fat. 
2.2. Adipose Tissue Biopsy and Measurement of Adipose Morphology 
GENiAL participants were examined in the morning after an overnight fast. Following a clinical 
examination, an abdominal SAT biopsy was obtained by a needle aspiration biopsy lateral to the 
umbilicus as described [17]. SAT samples were rapidly rinsed in sodium chloride (9 mg/mL) before 
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the removal of visual blood vessels and cell debris and subsequently subjected to collagenase 
treatment to obtain isolated adipocytes as described [18]. The mean weight and volume of adipocytes 
and their spontaneous lipolysis were determined as described [19,20]. A curve fit of the relationship 
between mean adipocyte volume and estimated abdominal subcutaneous fat mass (ESAT) was 
performed exactly as described [11]. This non-linear relationship for the GENiAL cohort is published 
in Andersson D et al. The difference between the measured and expected mean adipocyte volume at 
the corresponding fat mass determines adipose morphology [11]. If the measured adipocyte volume 
is larger than expected, SAT hypertrophy prevails, whereas the opposite is valid for hyperplasia. 
Thus, this measure of adipose morphology is independent of fat mass. 
2.3. Genetic Analysis 
Genotyping and quality control (QC) have been described [12]. After quality control, imputation 
was performed using the haplotype reference consortium panel and, when variants were not 
available, using the 1000G phase3 reference panel [21]. Post-imputation quality control excluded 
single nucleotide polymorphisms (SNPs) with minor allele count <3 and imputation quality 
information INFO <0.4 as well as related individuals (one of each pair of 1st or 2nd-degree relatives). 
After quality control, 894 samples and 9,714,326 SNPs were available for phenotypic analysis. A 
GWAS was conducted in PLINK 2.0 [22] using linear regression, assuming an additive genetic model, 
and adjusting for population structure (PCs1-3), age, and sex. Genome-wide significance was set at p 
<5 × 10−8, and suggestive significance was set at p < 1 × 10−5. Only SNPs with minor allele frequency 
(MAF) >1% were included in the results. Results were visualized using FUMA [23]. Data for one SNP 
included in the herein described GWAS is included in a separate manuscript by Carl Herdenberg E 
et al., where leucine-rich repeats and immunoglobulin-like domains 1 (LRIG) proteins regulate lipid 
metabolism via bone morphogenic (BMP) signaling and affect the risk of type 2 diabetes (submitted). 
This SNP displays a nominal association only with adipose morphology and is, therefore, not 
included in the presentation of GWAS results in the present study. 
2.4. Data Mining 
SNPs reaching GWAS or suggestive significance were examined for genotype-specific gene 
expression in adipose tissue (expression quantitative locus; eQTL) using GTEx database on January 
15, 2020 [24].  
2.5. Adipocyte Cell Culture and Transfection With Small Interfering RNA 
Isolation, growth, and differentiation of SAT-derived human mesenchymal stem cells (hMSCs) 
have been described previously [25]. Marker gene expression (Cap analysis gene expression (CAGE) 
and gene expression data) and lipid accumulation images for these cells have been published 
previously [26].  
hMSCs were transfected using a Neon electroporator (Invitrogen, Carlsbad, CA, US) according 
to the manufacturer’s protocol. Briefly, 1 million hMSCs at day -4 before initiation of differentiation 
were mixed with 40 nM ON-TARGETplus SMARTpool small interfering RNAs (siRNAs) targeting 
genes of interest or non-targeting siRNA pool (Dharmacon, Lafayette, CO, US) and electroporated 
using a 100 µL NEON electroporation tip. Electroporation conditions were 1150 Volts, 30 ms width, 
2 pulses. Electroporation was repeated until the required number of cells were collected for the 
experimental set-up. Following electroporation, the cells were plated in an antibiotic-free medium at 
the density of 55,000 cells/well in 24-well plates or 5500 cells/well in 96-well plate and cultured up to 
day 9 of differentiation as specified below.  
2.6. Measurement of Lipid Accumulation and Lipolysis 
Lipid accumulation was quantified at differentiation day 9. hMSCs differentiated in vitro were 
washed with PBS and fixed with 4% paraformaldehyde solution for 10 min at room temperature. 
Following fixation, neutral lipids were stained with Bodipy 493/503 (at 0.2 µg/mL; Molecular Probes, 
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Thermo Fisher Scientific, Waltham, MA, US), and nuclei (DNA) were stained with Hoechst 33342 (at 
2 µg/mL; Molecular Probes) for 20 min at room temperature. Accumulation of neutral lipids and cell 
numbers were quantified in CellInsight™ CX5 High Content Screening (HCS) Platform (Thermo 
Fischer Scientific, Waltham, MA, US) with integrated “Spot detection” protocol. Total Bodipy 
fluorescence (lipid droplets) was normalized to the number of nuclei, representing the number of 
cells in each well.  
The medium was collected at day 7 and 9 of differentiation of hMCSs for measuring glycerol 
release as an index of lipolysis, as described [27]. A standard curve ranging from 0 to 120 µM was 
used to calculate the concentrations of the samples. Amounts of glycerol was normalized to the 
number of nuclei and in each well. 
2.7. Analysis of Cell Proliferation  
hMSCs were electroporated using 10 µl NEON electroporation tip day -4 before initiation of 
differentiation. Electroporation conditions were 1150 Volts, 30 ms width, 2 pulses. Cells were 
incubated with media containing 5 µM 5-ethynyl-2′-deoxyuridine (EdU) at day -3 for 24 h, followed 
by an assessment of EdU-positive cells using the Click-iT®Plus EdU Alexa Fluor555 (C10352, 
Invitrogen, Carlsbad, CA). 
2.8. Isolation of RNA and Analysis of Gene Expression 
Following electroporation of siRNA, hMSCs were collected for isolation of RNA at the day 
differentiation was induced (day 0), days 1, and 7 post-induction of differentiation. Extraction of total 
RNA, measurement of concentration and purity as well as reverse transcription were performed as 
described [27]. Quantitative RT-PCR of coding genes was performed using commercial TaqMan 
probes (Applied Biosystems, Foster City, US). Gene expression was normalized to the internal 
reference gene 18s. Relative expression was calculated using the 2(−ΔΔ threshold cycle) method [28]. 
2.9. Statistical Analysis of Clinical and In Vitro Data 
Clinical and in vitro results are presented as mean ± standard deviation (SD). Glycerol and 
triglycerides values were normalized by log10 transformation prior to analysis. Standard statistical 
tests were used, including t-test, single or multiple regression as indicated in figure/table legends 
using Stat View software (Abacus Concepts Inc, Berkley, CA) or JMP 14 (SAS, NC, USA).  
3. Results 
3.1. Clinical Findings 
The demographic characteristics of the GENiAL cohort participants included in the GWAS of 
adipose morphology are presented in Table 1. The cohort consisted predominantly of women, who 
were younger and had a higher frequency of obesity than the men. Obesity was associated with 
higher systemic levels of fasting glucose and insulin, and with a pernicious lipid profile in both sexes. 
Average abdominal subcutaneous adipocyte volume was larger in obese subjects, whereas adipose 
morphology, as expected, was unrelated to obesity status. 
Table 1. Characteristics of participants in the GENetics of Adipocyte Lipolysis (GENiAL) cohort used 
for the analysis of adipose morphology. 
 Men Women 
 Non Obese Obese P 
Non 
Obese 
Obese P 
lean/obese (n) 155 91  261 441  
age (years) 47(14) 43(12) 0.01 40(13) 41(10) 0.38 
height (cm) 179(6) 181(7) 0.014 167(6) 166(7) 0.0044 
body weight (kg) 81(9) 125(18) <0.0001 67(9) 108(17) <0.0001 
BMI (kg/m2) 25(2) 38(5) <0.0001 24(3) 39(5) <0.0001 
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waist (cm) 93(8) 126(13) <0.0001 84(10) 119(13) <0.0001 
WHR 0.95(0.06) 1.05(0.05) <0.0001 0.86(0.07) 0.96(0.07) <0.0001 
systolic blood 
pressure (mm Hg) 
129(15) 140(18) <0.0001 120(16) 130(16) <0.0001 
diastolic blood 
pressure (mm Hg) 
79(10) 86(12) <0.0001 74(10) 79(10) <0.0001 
plasma total 
cholesterol (mmol/L) 
5.2(1.3) 5.3(1.4) 0.4 4.9(1.1) 5.0(1.0) 0.13 
plasma HDL 
cholesterol (mmol/L) 
1.3(0.4) 1.0(0.2) <0.0001 1.6(0.4) 1.2(0.3) <0.0001 
plasma 
triacylglycerides 
(mmol/l) 
1.72(2.1) 2.36(2.52) 0.044 1.07(0.64) 1.53(0.87) <0.0001 
plasma non-esterified 
fatty acids (mmol/L) 
0.49(0.17) 0.61(0.21) <0.0001 0.62(0.21) 0.72(0.24) <0.0001 
plasma glycerol 
(mmol/l) 
60.4(27.7) 78.5(30.2) <0.0001 81.4(43.0) 
116.8(54.3
) 
<0.0001 
fasting plasma 
glucose (mmol/L) 
5.5(1.2) 6.4(2.3) 0.0012 5.0(0.7) 5.6(1.4) <0.0001 
fasting serum insulin 
(mU/l) 
7.9(5.3) 20.8(11.8) <0.0001 6.2(3.3) 14.8(8.0) <0.0001 
HOMA-IR 2.0(2.0) 6.1(4.3) <0.0001 1.4(0.9) 3.8(2.9) <0.0001 
Cell volumn (pl) 503(142 826(192) <0.0001 474(179) 862(180) <0.0001 
Spontaneous lipolys 
(mmol 
glycerol/2hrs/ESAT) 
0.8(0.7) 3.8(2.7) <0.0001 1.0(0.9) 3.4(2.9) <0.0001 
Adipose morphology 
(pl) 
“−6(128)” 13(171 0.36 “−13(149) 10(168) 0.054 
Where: obese is defined as BMI>30 kg/m2; Spontaneous lipolysis rate was calculated as glycerol 
release divided by the lipid weight of the incubated fat cells; adipose morphology is difference 
between the measured and expected mean adipocyte volume at the abdominal subcutaneous adipose 
tissue depot. continuous variables are presented as mean (SD), groups were compared with Student’s 
t-test (unpaired). BMI, body mass index, WHR, waist hip ratio, HDL, high-density lipoprotein, 
HOMA-IR, homeostatic model assessment of insulin resistance, ESAT, estimated abdominal 
subcutaneous fat mass. 
Adipose morphology was correlated with insulin resistance as estimated by fasting serum (fS)-
Insulin (standardized beta 0.24, p 2 × 10−12), and HOMA-IR (standardized beta 0.16, p 1.5 × 10−6) after 
adjusting for age and sex. 
3.2. GWAS for Adipose Morphology 
The results of the GWAS are presented in Supplementary Figure 1, Table 2, and Supplementary 
Table 1. A total of 66 SNPs in 31 loci showed suggestive association (p < 10−5) with adipose 
morphology. Six genetic loci, each <1 Mb, contained >3 SNPs displaying suggestive association (p < 
10−5) with adipose morphology (Figure 1); subsequent analysis was focused on these genomic regions. 
The strongest association with adipose morphology was observed in a region on chromosome 3, 
where one SNP, rs2378515, displayed a borderline GWAS-significant association (p 5.20 × 10−8). This 
SNP is situated in the TP63 gene (Figure 1), which was not expressed in mature adipocytes, nor in 
our hMSCs during in vitro differentiation (results not shown) and could, therefore, not be taken 
forward for functional evaluation. No other gene is encoded within this LD-block bounded by a 
recombination fraction ~20% (Figure 1). On chromosome 2, we identified tag-SNP rs147711728 
among multiple SNPs (n = 6) of suggestive significance in the region that harbors the ATL2, CYP1B1, 
and RMD2 genes. On chromosome 6, tag-SNP rs62431222 defines a locus, which includes eight SNPs 
reaching suggestive significance and harboring genes L3MBTL3, SAMD3, and TMEM200A. 
Chromosome 8, with tag-SNP rs11988258 and three other SNP with suggestive association, had genes 
CLN8 and ARHGEF10 in the locus. On chromosome 9, tag-SNP rs145072648 is in a locus containing 
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the KLHL9 and the IFNA family of genes. The chromosome 17 locus includes three associated SNPs 
with tag-SNP rs201766885 and harbors FAM27L, MTRNR2L1, and C17orf51. 
Table 2. Tag SNPs associated with adipose morphology with p < 10-5. 
Chrom POS ID Effect Allele BETA L95 U95 P A1_FREQ 
1 3297459 rs201839757 I 198 113 283 5.75E-06 0.0126 
1 48004858 rs12032932 T 167 96 238 4.40E-06 0.0110 
1 76545413 rs10443175 T −40 −57 −22 8.15E-06 0.2247 
1 157782519 rs77346326 T 136 81 191 1.28E-06 0.0203 
2 19739010 rs3914966 T −34 −48 −19 4.64E-06 0.4256 
2* 38508250 rs147711728 T 164 93 234 6.30E-06 0.0108 
2 170990253 rs185528286 C 159 91 226 4.45E-06 0.0153 
3* 189410000 rs2378515 G 54 34 73 5.29E-08 0.1802 
4 170028965 rs202156267 A −164 −229 −99 9.12E-07 0.0313 
6 97632917 rs148707864 G 140 79 200 7.01E-06 0.0148 
6* 130581980 rs62431222 A 102 61 144 1.36E-06 0.0329 
7 52698748 rs150804725 I −112 −159 −64 4.65E-06 0.0297 
7 156412814 rs849073 G −34 −48 −19 9.16E-06 0.4351 
8* 1784364 rs11988258 A −34 −48 −20 4.06E-06 0.4201 
8 32613177 rs75468268 G 155 87 223 8.95E-06 0.0134 
8 69224040 rs814465 C 82 49 114 1.04E-06 0.0537 
8 141147356 rs142956251 A 155 87 224 8.43E-06 0.0139 
9* 21340235 rs145072648 C 163 97 230 1.59E-06 0.0126 
9 30859764 rs138591003 A −178 −255 −100 7.76E-06 0.0108 
10 97277536 rs189712177 G 186 107 265 4.43E-06 0.0115 
10 128606691 rs71490795 A 121 69 174 6.52E-06 0.0225 
11 23509085 rs148697259 A 133 75 192 9.22E-06 0.0181 
11 99369450 rs72991567 G 67 39 95 2.54E-06 0.0804 
12 73510344 rs60148685 D 34 19 48 8.09E-06 0.4437 
13 30571045 rs200421910 I −64 −92 −36 8.33E-06 0.0988 
13 109383269 rs151235076 T 188 108 267 4.27E-06 0.0097 
16 2390565 rs45501400 T 169 94 243 9.89E-06 0.0163 
17* 22020568 rs201766885 C 113 65 161 4.24E-06 0.0464 
19 53280252 rs10414169 T 131 74 189 8.82E-06 0.0183 
22 32558640 rs144964180 A 160 90 229 7.28E-06 0.0122 
22 49801423 rs9627723 C 45 26 64 4.15E-06 0.3654 
* Tag-SNP in regions with >3 SNPs with p < 10−5 for association with adipose morphology. Only results 
for SNPs with minor allele frequency (MAF)>1% are shown. I = insertion; D = deletion. SNP, single 
nucleotide polymorphism, Chrom, chromosome, POS, position in the genome, ID, reference SNP 
accession number, BETA, beta coefficient, L95, lower 95% confidence interval, U95, upper 95% 
confidence interval, A1_FREQ, frequency of effect allele. 
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Figure 1. Genetic loci demonstrating suggestive association with adipose morphology. 
All 66 SNPs in Supplementary Table 1 were investigated in the GTEx eQTL resource, but failed 
to provide evidence for genotype-dependent gene expression in SAT. All SNPs resided in regions 
that do not encode protein and are, therefore, of unclear impact. 
3.3. Functional Evaluation of Candidate Genes 
Transcriptome profiling of all protein-coding genes in the six adipose morphology-associated 
genetic loci revealed six genes from four loci, which were expressed in adipocytes and their 
progenitors isolated from SAT biopsies, as well as in hMSCs undergoing in vitro differentiation to 
adipocytes. (Figure 2A,B). The six genes were taken forward for functional evaluation in hMSCs to 
determine possible impact on adipogenesis. All genes except C17orf51 were enriched in progenitor 
cells as compared to mature adipocytes (Figure 2A). The expression of CYP1B1, TMEM200A, and 
ARHGEF10 decreased directly after induction of differentiation, whereas the expression of ATL2, 
C17orf51, and L3MBTL3 varied over the course of differentiation of hMSCs (Figure 2B).  
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Figure 2. (A) Expression of candidate genes during human mesenchymal stem cell (hMSC) 
differentiation in vitro. (B) Enrichment of candidate genes in progenitor cells and mature adipocytes. 
Data retrieved from the FANTOM5 dataset (http://fantom.gsc.riken.jp/5/) and Ehrlund, A et al. 
2017 [29]. 
Based on the expression pattern during differentiation, we knocked down the aforementioned 
candidate genes in hMSCs during proliferation, that is four days prior to induction of differentiation 
where day 0 corresponds to the start of differentiation. This resulted in a 60–80% decreased 
expression in all candidate genes except L3MBTL3, where the efficiency of knockdown was 20–60% 
(Figure 3A). We evaluated the accumulation of neutral lipids as a marker of adipocyte differentiation 
(Figure 3B, Figure S2) and the release of glycerol in cell culture medium as a marker of adipocyte 
lipolysis at day 9 of differentiation (Figure 3C). Both the accumulation of lipids and glycerol levels 
were reduced after knockdown of all six genes. We observed a ~5–10% increase in cell number in 
knockdown of ATL2, ARHGEF10, CYP1B1, and TMEM200A and a modest reduction in cell number 
in knockdown of L3MBTL3 (Figure 4A). To investigate cell proliferation, we knocked down the 
candidate genes, and treated cells in each experiment with EdU, a marker of DNA synthesis in 
proliferating cells. The proportion of proliferating cells (EdU+) was ~5–16% higher for all genes, 
although for L3MBTL3, the increase was modest (Figure 4B); however, this might be related to poor 
knockdown efficiency of L3MBTL3 (Figure 3A). Furthermore, the expression of the marker of 
proliferation Ki-67 (mKi67) was increased day 0 before initiation of differentiation for all investigated 
genes (Figure 4C).  
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Figure 3. (A) ATL2, ARHGEF10, CYP1B1, TMEM200A, C17orf51, and L3MBTL3 was knocked down 
using small interfering RNAs (siRNA) in hMSCs four days (day -4) before induction of differentiation 
and followed until differentiation day 7 and 9. (B) Accumulation of neutral lipids was evaluated with 
Bodipy staining of cells at day 9. (C) Glycerol amount in the medium was measured, and all measured 
concentrations were within the range of the glycerol standard curve 0–120 µM. Results were analyzed 
using a t-test and presented in fold change ± SD relative to negative control of a corresponding time 
point (Neg C). ***p < 0.005, **p < 0.01, *p < 0.05. 
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Figure 4. (A) Cell number at day 9 of differentiation was measured by Hoechst staining of nuclei. (B) 
Cell proliferation was evaluated by measuring DNA-synthesis with 5-ethynyl-2′-deoxyuridine (EdU). 
(C) mRNA-levels of proliferation marker mKI67 were measured with real-time qPCR at day 0 before 
differentiation was initiated. Results were analyzed using a t-test and presented in fold change ± SD 
relative to negative control of a corresponding time point (Neg C). ***p < 0.005, **p < 0.01, *p < 0.05. 
Expression levels of genes central to adipogenesis (peroxisome proliferator-activated receptor-
gamma (PPARG), CCAAT/enhancer-binding protein alpha (CEBPA) and CCAAT/enhancer-binding 
protein beta (CEBPB) and the adipocyte marker adiponectin (ADIPOQ) were measured in each 
knockdown experiment (Figure 5) at differentiation start (day 0), day 1 day, and day 7 post 
differentiation induction. Knockdown of ATL2 resulted in a reduced expression of all adipogenesis 
genes (Figure 5A). ARHGEF10 knockdown resulted in a temporary modest reduction in the 
expression of CEBPA and CEBPB (Figure 5B). The knockdown of CYP1B1 resulted in reduced 
expression of PPARG, CEBPB, and ADIPOQ, and a modest reduction in CEBPA expression (Figure 
5C). The knockdown of TMEM200A and L3MBTL3 resulted in a reduced expression of investigated 
adipogenesis genes, although the effect on PPARG expression was modest (Figure 5D,F). The 
knockdown of C17orf51 resulted in a strong reduction in ADIPOQ expression and a modest effect on 
the expression of adipogenesis genes (Figure 5E). 
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Figure 5. (A–F) The expression of peroxisome proliferator-activated receptor-gamma (PPARG), 
CCAAT/enhancer-binding protein alpha (CEBPA), and CCAAT/enhancer-binding protein beta 
(CEBPB) measured on day 0, 1, and 7. The expression of ADIPOQ was only measured at day 7. Results 
are based on three biological/independent experiments. Expression of genes was normalized to the 
reference gene 18s. Results were analyzed using a t-test and presented in fold change ± SD relative to 
negative control of a corresponding time point (Neg C). ***p < 0.005, **p < 0.01, *p < 0.05. 
3.4. SAT-Expression of CYP1B1 and ATL2 Correlates With Adipose Morphology 
We next examined whether abdominal SAT expression of the six candidate genes was associated 
with adipose morphology using SAT-expression from a previously examined cohort of 114 women 
where adipose morphology was quantified as average adipocyte size in the abdominal SAT region 
adjusted for total body fat [16]. There was an inverse relationship between ATL2 expression and 
adipose morphology (p 4.00 × 10−4, R = 0.33) and a positive association between CYP1B1 and adipose 
morphology (p 3.01 × 10−6, R = 0.43). No association between ARHGEF10, TMEM200A, L3MBTL3, and 
C17orf51 and adipose morphology was observed. 
3.5. Overlap Between Result From GWAS Studies of T2D and Adipose Morphology  
None of the SNPs demonstrating suggestive association with adipose morphology have 
previously been associated with clinical metabolic traits, such as IR or T2D, according to the GWAS 
catalog (https://www.ebi.ac.uk/gwas/), February 14th, 2020). However, 25 genetic loci previously 
associated with T2D demonstrated nominal association with adipose morphology (Table 3). In 12 
genetic loci, the allele increasing the risk of T2D was associated with adipose hypertrophy consistent 
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with the finding that this adipose morphology increases the risk for T2D in genetic epidemiological 
studies [9]. None of these genetic loci encoded genes with established roles in human SAT. For the 
remaining loci, the risk allele is either not reported in the GWAS catalog, or the allele increasing the 
risk of T2D is associated with hyperplastic SAT making it difficult to interpret the finding.  
Table 3. Tag genome-wide association study (GWAS) SNPs associated with type 2 diabetes and with 
adipose morphology in the current study. 
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   GWAS Adipose Morphology GWAS Catalogue T2D  Consistent Risk Alleles For  
SNP CHROM POS A1 A1_FREQ BETA P PUBMED Reported Genes Risk Allele OR BETA Adipose Hypertrophy and T2D 
rs12031188 1 51103268 C 0.40 15 4.50E-02 30718926 FAF1 C 1.08 yes 
rs58432198 1 51256091 T 0.11 −24 4.58E-02 30718926 FAF1 C 1.10 no 
rs2088315 3 162382517 G 0.50 16 3.27E-02 30130595 OTOL1, LINC01192 ? 5.26 not reported 
rs8192675 3 170724883 C 0.30 17 4.13E-02 28566273 NR T 1.05 no 
rs138306797 3 185545719 T 0.02 76 1.32E-02 25760438 IGF2BP2 ? 0.78 not reported 
rs9379084 6 7231843 A 0.10 −48 2.94E-04 29632382 RREB1 G 1.09 yes 
rs9460550 6 20719561 A 0.16 26 1.01E-02 31118516 CDKAL1 A 1.15 yes 
rs72892910 6 50816887 T 0.20 −18 4.61E-02 30054458 TFAP2B T 0.06 yes 
rs9384193 6 154554249 C 0.38 −16 3.97E-02 28060188 OPRM1, CNKSR3 ?  not reported 
rs10231619 7 43320594 T 0.16 41 7.18E-05 25102180 HECW1 T 1.13 yes 
rs4729854 7 102383663 A 0.47 −18 2.00E-02 30595370  ?  not reported 
rs896854 8 95960511 C 0.47 20 8.30E-03 20581827 TP53INP1 T 1.06 no 
           no 
rs10761745 10 65101071 G 0.14 −28 9.68E-03 28406950 JMJD1C ? 1.20 not reported 
rs4929965 11 2197286 A 0.37 16 4.17E-02 30718926 INS, IGF2 A 1.12 yes 
rs2237892 11 2839751 T 0.07 −47 1.12E-03 22961080 KCNQ1 C 1.32 yes 
rs2722769 11 11228374 G 0.42 −16 3.48E-02 22238593 GALNTL4, LOC729013 C 1.35 unclear 
rs7931302 11 128236058 C 0.29 19 1.92E-02 30054458 ETS1 C 0.05 yes 
rs11048456 12 26463082 C 0.26 −17 4.66E-02 30054458 ITPR2 C 0.05 yes 
rs1153188 12 55098996 T 0.26 21 1.79E-02 18372903 DCD A 1.08 no 
rs730570 14 101142890 G 0.18 −20 3.74E-02 21573907 C14orf70 G 1.14 no 
rs1436955 15 62404382 T 0.28 −17 3.62E-02 20862305 C2CD4B C 1.13 yes 
rs781852 17 3953102 G 0.36 17 3.43E-02 29632382 ZZEF1 G 1.05 yes 
rs11873305 18 58049192 C 0.04 54 1.04E-02 22885922 MC4R A 1.18 no 
rs7274168 20 32435978 C 0.41 −20 8.28E-03 30595370  ?  not reported 
rs6017317 20 42946966 G 0.23 17 4.06E-02 22158537 FITM2, R3HDML, HNF4A G 1.09 yes 
rs16988991 20 42989777 A 0.20 17 4.63E-02 30718926 HNF4A A 1.05 yes 
rs2833610 21 33385186 A o -17 2.75E-02 21490949 HUNK A 1.17 no 
Where A1 = effect allele; GWAS, genome-wide association study, T2D, type 2 diabetes, SNP, single nucleotide polymorphism, CHROM, chromosome, POS, position in the 
genome, A1_FREQ, frequency of effect allele, BETA, beta coefficient, OR, Odds Ratio.
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4. Discussion 
The present study has shed new light on the genetics of adipose morphology, identified six 
genetic loci harboring candidate genes, and provides evidence for these candidate genes as regulators 
of adipocyte renewal and lipid storage in adipose hypertrophy. Hypertrophic SAT morphology is a 
strong risk factor for IR and T2D. However, among established risk alleles for T2D from GWAS, only 
12 alleles were nominally associated with hypertrophic adipose morphology. 
In the adipose morphology-associated locus on chromosome 2, functional analysis by siRNA-
mediated knockdown suggested CYP1B1 and/or ATL2 as potential causal links between genetic 
variants and adipose morphology. The knockdown of either gene stimulated proliferation of adipose-
derived hMSCs accompanied by reduced expression of mRNA markers for adipogenesis, inhibited 
lipid accumulation, and reduced lipolysis in cells. Our interpretation of these findings is that a higher 
number of precursor cells resulted in a lower proportion of differentiating cells, i.e., reduced 
expression of adipogenesis markers and reduced lipid accumulation, rather than impaired 
adipogenesis. This interpretation is consistent with the finding that increased recruitment of new fat 
cells is a major determinant of adipose hyperplasia [4]. The expression pattern of CYP1B1 and ATL2 
did not permit knockdown late in differentiation and, therefore, we could not determine whether 
these genes have a direct impact on mature fat cell lipid accumulation, or whether the lipid phenotype 
is secondary to a larger number of progenitor cells in the experiment. In either case, our findings 
support the hypothesis that CYP1B1 and ATL2 counteract a favorable hyperplastic adipose expansion 
by inhibiting the proliferation of precursor cells. The evidence for CYP1B1 was further supported by 
the finding of a positive association between SAT gene expression of CYP1B1 and hypertrophic 
adipose morphology in a large clinical cohort. CYP1B1 encodes a widely expressed monooxygenase 
involved in the metabolism of many important physiological compounds, including estrogen, 
arachidonic acid, melatonin, and retinoids [30]. CYP1B1-null mice display attenuated high-fat diet 
(HFD)-induced obesity and improved glucose tolerance related to increased fatty acid oxidation 
markers [31–33]. In mouse models, CYP1BI has been reported to control PPARG expression, whereas 
no impact on adipogenesis was observed [30]. The other candidate gene on chromosome 2, ATL2, has 
been reported to influence lipid droplets via the endoplasmatic reticulum [34]. The chromosome 2 
locus, but not the SNPs reported herein, has previously been associated with BMI in GWAS [35]. 
Together previous and present findings give support to the notion that the chromosome 2 locus, 
possible via CYP1B1 and/or ATL2, controls the extent and fate of adipose expansion. 
On chromosome 3, multiple SNPs in an intron of the TP63 gene displayed association with 
adipose morphology. Due to the high recombination in this locus, the association does not extend 
beyond the TP63 gene. TP63-/- mice develop obesity and insulin resistance linked to increased fatty 
acid synthesis and decreased fatty acid oxidation [36]. None of the reported TP63 splice variants were 
detected at mRNA level in our in vitro system (adipose derived hMSCs) nor in mature adipocytes 
isolated from adipose tissue, and, therefore, we could not assess the function of TP63 in human 
adipocytes. Further characterization of the potential role of TP63 in human adipose tissue will need 
more refined methods, cell models, and methods that were beyond the scope of this study.  
In the chromosome 6 locus, knockdown of L3MBTL3 and TMEM200A reduced lipid 
accumulation in fat cells. For TMEM200A, the finding was accompanied by the proliferation of 
adipose-derived hMSCs. The L3MBTL3 locus has recently been reported to be associated with 
systemic IR and lower levels of peripheral fat, and the encoded protein to stimulate adipocyte fat 
storage [10]. The herein reported association of the L3MBTL3 with hypertrophic adipose morphology 
potentially expands the knowledge of how this locus influences IR. We did not find any previous 
data on TMEM200A and metabolic disease; additional studies are needed to determine the 
importance of this gene for adipose function. 
Finally, loci on chromosomes 8 and 17 were associated with adipose morphology. In these loci, 
knockdown of the ARHGEF10 and C17orf51 genes, respectively, promoted precursor cell proliferation 
and inhibited lipid accumulation, which could explain the association between these genetic loci and 
adipose morphology. ARHGEF10 belongs to the Rho guanine nucleotide exchange factor (GEF) 
family, which stimulates Rho GTPases and has been shown to have tumor suppressor activity and 
Cells 2020, 9, 1085 15 of 17 
 
inhibits proliferation [37]. Beyond this, the function of these genes is poorly defined, and these genetic 
loci have not previously been implicated in the control of common metabolic disorders according to 
the GWAS catalog (https://www.ebi.ac.uk/gwas/). 
SAT adipose morphology, as measured herein, categorizes the studied adipose depot as 
hypertrophic or hyperplastic, i.e., larger or smaller fat cells than expected given the size of the fat 
depot. In general, both average adipocyte volume and numbers increase with increasing BMI. An 
advantage with the applied measure of adipose morphology is that it takes the size of the fat depot 
into account. At the same time, adipose morphology, hereby, becomes a complex phenotypic 
outcome potentially dependent on genes controlling adipocyte number, lipid droplet size, as well as 
total body fat. In the present study, we chose to focus on precursor cell proliferation and lipid droplet 
size as potential functional links between candidate genes and adipose morphology. An appropriate 
functioning adipogenesis is essential for healthy lipid storage in subcutaneous AT. Inappropriate AT 
expansion, as observed with hypertrophic SAT, promotes ectopic lipid storage and systemic IR [10]. 
The reduced glycerol release observed after knockdown of candidate genes gives further support to 
the notion of impaired adipogenesis. The complexity of the phenotype might explain why most 
examined genes did not show an association between adipose gene expression and morphology. 
One weakness of the present study is that we were unable to link SAT morphology associated 
SNPs functionally to specific genes, i.e., none of the morphology-associated SNPs were eQTLs in SAT 
or visceral adipose tissue or caused direct deleterious effects on gene function, e.g., missense 
mutations, according to bioinformatic analysis. Another weakness is the limited power of the study 
cohort. The latter is unavoidable for a phenotype, such as adipose volume, which is very resource-
demanding to collect. However, the results of the functional exploration of genes in the identified 
morphology-associated loci provide validation for the approach. Finally, we only assessed SAT 
morphology although other adipose depots might be even more relevant to study [38], but are even 
less accessible for sampling. 
In conclusion, our genetic and functional findings provide evidence for ATL2, ARHGEF10, 
CYP1B1, TMEM200A, C17orf51, and L3MBTL3 being important for adipose tissue morphology by 
regulation of proliferation and differentiation of precursor cells. Further work would be required to 
determine whether modulation of these genes could have therapeutic applications in IR and T2D, 
where adipogenesis is perturbed 
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